CASI PHARMACEUTICALS, INC. (NASDAQ:SPPI) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01.Entry into a Material Definitive Agreement.
On December 13, 2016, CASI Pharmaceuticals, Inc. (the Company)
entered into a Second Amendment to Secured Promissory Note (the
Second Amendment) with Talon Therapeutics, Inc. (Talon), an
affiliate of Spectrum Pharmaceuticals, Inc.
As previously reported, the Company delivered to Talon a $1.5
million Secured Promissory Note on September 17, 2014 (the Note),
and amended on September 28, 2015 (the First Amendment), in
connection with the exclusive license to the commercial oncology
drug, MARQIBO (vinCRIStine sulfate LIPOSOME injection) in greater
China, including Taiwan, Hong Kong and Macau. The Note had a
maturity date of March 17, 2016. to the First Amendment, the
Company and Talon agreed to change the maturity date of the Note
to March 17, 2017. to the Second Amendment, the Company and Talon
agreed to change the maturity date of the Note to March 17, 2018.
All other terms remain the same. A copy of the Second Amendment
is filed as Exhibit 4.3 to this Current Report on Form 8-K and
incorporated herein by reference.
Item 9.01.Financial Statements and Exhibits.
| (d) | Exhibits |
| Exhibit Number | Description | ||
| 4.1 |
Secured Promissory Note, dated as of September 17, 2014, issued to Talon Therapeutics, Inc. (incorporated by reference to Exhibit 4.2 of the Companys Current Report on Form 8-K filed on September 19, 2014) |
||
| 4.2 |
First Amendment to Secured Promissory Note, dated as of September 28, 2015, by and between the Company and Talon Therapeutics, Inc. (incorporated by reference to Exhibit 4.2 of the Companys Current Report on Form 8-K filed on October 1, 2015) |
||
| 4.3 |
Second Amendment to Secured Promissory Note, dated as of December 13, 2016, by and between the Company and Talon Therapeutics, Inc. (filed herewith) |
About CASI PHARMACEUTICALS, INC. (NASDAQ:SPPI)
Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin’s lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has two drugs in late-stage development: SPI-2012, which is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. It has a product portfolio consisting of both commercial-stage and development-stage products that address various cancer types. Its commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. Its other products include SPI-2012, POZIOTINIB and EOQUIN. CASI PHARMACEUTICALS, INC. (NASDAQ:SPPI) Recent Trading Information
CASI PHARMACEUTICALS, INC. (NASDAQ:SPPI) closed its last trading session up +0.05 at 4.68 with 867,617 shares trading hands.
